ArticleBrain communications2025
Anterograde and trans-synaptic neurodegeneration in aquaporin-4-antibody neuromyelitis optica spectrum disorder patients with a history of transverse myelitis.
Article in Brain communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuromyelitis optica spectrum disorder associated with aquaporin-4-antibodies (AQP4-NMOSD) is an autoimmune disease of the CNS with a high risk of visual, motor and sensory disability secondary to optic neuritis (ON) and transverse myelitis (TM) attacks. The degree of recovery is difficult to predict and may be affected by the extent of ensuing neurodegeneration. While neurodegeneration in AQP4-NMOSD is reported in the visual system after ON, its occurrence in patients with TM remains largely unknown. The aim of this study was to use advanced MRI to cross-sectionally examine the sensory and motor pathways in 18 AQP4-NMOSD patients with a history of TM and 20 healthy controls. The results showed that AQP4-NMOSD patients had decreased cross-sectional area (mean 63.62 versus 70.75,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.